Key Takeaways
- Soft quarter, margin-led beat: Domestic volume declined amid a weak summer and muted rural discretionary spend, but gross margin expanded 60 bps to 63.1% as input costs eased, driving a 22% EBITDA jump.
- Summer portfolio dragged the topline: Unseasonal rains across India depressed Navratna and the broader summer range for two months, masking momentum in pain management, Kesh King, and Fair and Handsome.
- Start-up bets are scaling, not yet contributing: The Man Company and Brillare brought digital insights, but Brillare’s underperformance forced an INR32 cr impairment in standalone books. Management expects 50-60% growth from start-ups in FY24.
- International business was the standout: Delivered stellar growth despite currency crises in Bangladesh, Sri Lanka, and Nepal, and conflict in the CIS region, powered by power brands in MENA, CIS, and Bangladesh.
- What to watch next quarter: Whether the hospital deal closes within the promised 3-4 weeks, the pace of rural recovery as monsoon and crop realization improve, and if the summer portfolio can salvage growth in the remaining month.
Demand & Volume Reality
- Domestic volume declined: Organic volume growth was negative when stripping out Dermicool and The Man Company contributions, per an analyst's math. Management confirmed the negative figure without disclosing the exact number.
- Rural stress persists: Discretionary categories like personal care remain muted as rural consumers cut nonessential spending. The summer portfolio was hit hardest by unseasonal rains, though some momentum is now visible from rural markets.
- Channel mix shifting: Modern trade and e-commerce continued to grow, reducing dependency on the wholesale channel. The rural expansion project (Project Khoj) added 11,000 towns, reaching 52,000 towns and villages, but management flagged that directive expansion could cause some fallout in wholesale, where they have less control.
- Bright spots outside summer: Pain management, Fair and Handsome (up 29% on a weak base), Kesh King, and healthcare are all performing well, giving management confidence that the underlying portfolio is sound.
Mohan Goenka: "If the summer would have been favorable, then I'm sure the growth would have been very good."
Margin & Cost Structure
- Gross margin expanded 60 bps to 63.1%: Input cost pressure has meaningfully eased, creating headroom to reinvest in advertising across most categories.
- EBITDA grew 22%: The expansion came despite absorbing costs from newly integrated subsidiaries (The Man Company) and distribution project spends, both absent from the base quarter.
- Standalone other expenses spiked: The jump was driven by a cancelled dividend from Emami Bangladesh, which could not remit funds to India due to forex problems.
- Brillare Science impairment: A INR32 cr impairment was taken in standalone books for the strategic investment, as actual growth fell short of projections. At the consolidated level, an additional INR8-9 cr impairment hit intangible assets, booked at a conservative valuation.
- FY24 margin outlook: Management expects ~150 bps gross margin expansion and is very confident of achieving more than 27% core margins if the raw material easing trend holds. Ad spend is guided to 16.5-17% of revenue.
Mohan Goenka: "What is very, very heartening is that the input cost pressure has really eased and we are seeing margin expansion. So we would be able to put in some money on advertising on most of our categories."
Portfolio & Brand Health
- Market shares held: Sustained interventions and marketing ensured brands cemented leadership positions despite the demand softness. Most major brands increased household penetration during FY23.
- Kesh King turning around: The brand is performing better than previous quarters, supported by a new small-size bridge pack launch. Management is confident of ~10% growth if momentum continues.
- Fair and Handsome base effect: The 29% Q4 growth was primarily a recovery from a poor COVID-hit base last year; growth has since moderated to single digits.
- Dermicool vs Navratna distinct: Dermicool is positioned as a prickly heat powder, while Navratna cool talc is a general-purpose cooling powder. They do not compete with each other.
- Digital-first innovation: The majority of ~20 products launched in FY23 were digital-first on the D2C portal Zandu Care. Future new product development will remain primarily in D2C, focusing on digital-first and premium categories.
Healthcare & Hospital Deal
- Healthcare base effect ending: The healthcare range declined due to the base effect of COVID-related immunity product surges (Chyawanprash during April-June '21 and the January-February '22 Omicron wave). Management expects both OTC and medical businesses to return to growth from this quarter onward, guiding 15-20% growth for FY24.
- Hospital deal awaiting government nod: The transaction is signed and sealed, with only government approval pending. Management expects the deal to conclude in a maximum of 3-4 weeks. Once materialized, it will reduce promoter pledge. If the deal fails, management will return to the drawing board for alternatives but expressed high confidence it will close.
Mohan Goenka: "The deal is signed, sealed, everything. We are just awaiting government approval. As soon as we get it, the transaction would conclude. It's just a matter of time. I think max of about 3 weeks to 4 weeks, that's what we think."
International & Start-up Bets
- International business defied macro headwinds: Delivered stellar performance despite high inflation, currency depreciation in Bangladesh, economic crisis in Sri Lanka, forex and liquidity crisis in Nepal, and ongoing political conflicts in CIS countries. Growth was driven by power brands in MENA, CIS, and Bangladesh. Management expects at least 20% growth in FY24.
- Start-up investments yielding insights: Investments in The Man Company and Brillare have accelerated digital learning and growth levers, even as Brillare's financial underperformance triggered impairments.
- The Man Company profitability expected in FY24: Management is bullish, guiding at least 50-60% growth from start-ups overall, with heavy investment planned in male grooming and new launches. The Man Company is expected to turn profitable this year.
- Rural distribution model validated: Project Khoj used a category-potential lens rather than concentric circles to drive distribution, yielding a very high repeat rate of more than 85% per month.
Vinod Nandgopal Rao: "We looked at potential, potential with respective in our categories, and we drove distribution in that manner. So that gave us a lot of confidence because we've got a very high repeat rate."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic business growth | 8-10% growth if trend continues | FY24 |
| International business growth | At least 20% growth | FY24 |
| Healthcare business growth | 15-20% growth | FY24 |
| Start-up portfolio growth | At least 50-60% growth | FY24 |
| The Man Company profitability | Turn profitable | FY24 |
| Gross margin expansion | ~150 bps expansion | FY24 |
| Core margins | More than 27% if raw material easing continues | FY24 |
| Advertising spend | 16.5-17% of revenue | FY24 |
| Tax rate | Similar to FY23; MAT credit utilization starts | FY27 |
| Hospital deal closure | Government approval and transaction conclusion | Max 3-4 weeks |
| Pledge reduction | Upon hospital deal materialization | Contingent on deal |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹836 cr (per an analyst's math), +2% volume growth; Dermicool and The Man Company contributed ~10% to topline |
| Gross margin | 63.1%, expanded 60 bps YoY |
| EBITDA | ₹200 cr, +22% YoY; margin at 23.9%, expanded 260 bps YoY |
| EBITDA margin (ex-strategic investments) | 26.7% for FY23, close to pre-COVID levels |
| Profit before tax | ₹148 cr, +51% YoY |
| Profit before tax (FY23) | ₹670 cr, -3% YoY, +14% on 4-year CAGR basis |
| Domestic volume growth | 2% overall; organic volume growth was negative |
| International business growth | +19% YoY in Q4, +20% in FY23 |
| Modern trade growth | +18% YoY |
| E-commerce growth | +64% YoY |
| Modern trade and e-commerce saliency | >20% of domestic sales, +500 bps YoY |
| Healthcare range growth | -13% YoY in Q4, +8% on 4-year CAGR basis |
| Male grooming segment growth | +29% YoY, primarily due to base impact |
| Advertising spend | 15.5% of net sales in FY23, down ~300 bps YoY; expected 16.5%-17% in FY24 |
| Employee cost growth | +16.8% YoY; ~10-11% excluding The Man Company integration |
| Other expenses growth | +20% YoY; includes ~₹9-10 cr from The Man Company and distribution project costs |
| Impairment (Brillare Science) | ₹32 cr in standalone other expenses; ₹8-9 cr in consolidated intangible assets |
| Rural distribution reach | 52,000 towns and villages, up from 32,000 two years ago; added ~11,000 towns in FY23 |
| Chemist coverage | 1.3 lakh chemists across India |
| The Man Company growth | ~40% in FY23; expected to be profitable in FY24 |
| Domestic business growth guidance (FY24) | 8-10% expected, with ~3-3.5% from price increases |
| International business growth guidance (FY24) | At least 20% expected |
| Healthcare business growth guidance (FY24) | 15-20% expected |
| Gross margin expansion expectation (FY24) | ~150 bps expansion expected |